| Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM L Fontana, ME Fiori, S Albini, L Cifaldi, S Giovinazzi, M Forloni, R Boldrini, ... PloS one 3 (5), e2236, 2008 | 475 | 2008 |
| Influence of the tumor microenvironment on NK cell function in solid tumors O Melaiu, V Lucarini, L Cifaldi, D Fruci Frontiers in immunology 10, 3038, 2020 | 371 | 2020 |
| Inhibition of natural killer cell cytotoxicity by interleukin‐6: implications for the pathogenesis of macrophage activation syndrome L Cifaldi, G Prencipe, I Caiello, C Bracaglia, F Locatelli, F De Benedetti, ... Arthritis & rheumatology 67 (11), 3037-3046, 2015 | 301 | 2015 |
| Impaired natural and CD16-mediated NK cell cytotoxicity in patients with WAS and XLT: ability of IL-2 to correct NK cell functional defect A Gismondi, L Cifaldi, C Mazza, S Giliani, S Parolini, S Morrone, ... Blood 104 (2), 436-443, 2004 | 186 | 2004 |
| ADAR2-editing activity inhibits glioblastoma growth through the modulation of the CDC14B/Skp2/p21/p27 axis F Galeano, C Rossetti, S Tomaselli, L Cifaldi, M Lezzerini, M Pezzullo, ... Oncogene 32 (8), 998-1009, 2013 | 157 | 2013 |
| Cellular and gene signatures of tumor-infiltrating dendritic cells and natural-killer cells predict prognosis of neuroblastoma O Melaiu, M Chierici, V Lucarini, G Jurman, LA Conti, R De Vito, ... Nature Communications 11 (1), 5992, 2020 | 119 | 2020 |
| IRF1 and NF-kB restore MHC class I-restricted tumor antigen processing and presentation to cytotoxic T cells in aggressive neuroblastoma S Lorenzi, M Forloni, L Cifaldi, C Antonucci, A Citti, R Boldrini, M Pezzullo, ... Public Library of Science 7 (10), e46928, 2012 | 115 | 2012 |
| NF-κB, and not MYCN, regulates MHC class I and endoplasmic reticulum aminopeptidases in human neuroblastoma cells M Forloni, S Albini, MZ Limongi, L Cifaldi, R Boldrini, MR Nicotra, ... Cancer research 70 (3), 916-924, 2010 | 112 | 2010 |
| Role of endoplasmic reticulum aminopeptidases in health and disease: from infection to cancer L Cifaldi, P Romania, S Lorenzi, F Locatelli, D Fruci International journal of molecular sciences 13 (7), 8338-8352, 2012 | 101 | 2012 |
| CD56highCD16− CD62L− NK cells accumulate in allergic contact dermatitis and contribute to the expression of allergic responses T Carbone, F Nasorri, D Pennino, K Eyerich, S Foerster, L Cifaldi, ... The journal of immunology 184 (2), 1102-1110, 2010 | 94 | 2010 |
| Natural killer cells efficiently reject lymphoma silenced for the endoplasmic reticulum aminopeptidase associated with antigen processing L Cifaldi, E Lo Monaco, M Forloni, E Giorda, S Lorenzi, S Petrini, ... Cancer research 71 (5), 1597-1606, 2011 | 92 | 2011 |
| Proline-rich tyrosine kinase 2 and Rac activation by chemokine and integrin receptors controls NK cell transendothelial migration A Gismondi, J Jacobelli, R Strippoli, F Mainiero, A Soriani, L Cifaldi, ... The Journal of Immunology 170 (6), 3065-3073, 2003 | 78 | 2003 |
| ERAP1 regulates natural killer cell function by controlling the engagement of inhibitory receptors L Cifaldi, P Romania, M Falco, S Lorenzi, R Meazza, S Petrini, ... Cancer research 75 (5), 824-834, 2015 | 74 | 2015 |
| Regulation of ERAP1 and ERAP2 genes and their disfunction in human cancer M Compagnone, L Cifaldi, D Fruci Human immunology 80 (5), 318-324, 2019 | 72 | 2019 |
| TIM-3/Gal-9 interaction induces IFNγ-dependent IDO1 expression in acute myeloid leukemia blast cells V Folgiero, L Cifaldi, GL Pira, BM Goffredo, L Vinti, F Locatelli Journal of hematology & oncology 8, 1-5, 2015 | 63 | 2015 |
| Interleukin 12-activated lymphocytes influence tumor genetic programs F Cavallo, E Quaglino, L Cifaldi, E Di Carlo, A André, P Bernabei, ... Cancer research 61 (8), 3518-3523, 2001 | 60 | 2001 |
| Boosting natural killer cell-based immunotherapy with anticancer drugs: a perspective L Cifaldi, F Locatelli, E Marasco, L Moretta, V Pistoia Trends in Molecular Medicine 23 (12), 1156-1175, 2017 | 56 | 2017 |
| Major histocompatibility complex class i and tumour immuno-evasion: how to fool T cells and natural killer cells at one time D Fruci, M Benevolo, L Cifaldi, S Lorenzi, EL Monaco, E Tremante, ... Current Oncology 19 (1), 39, 2012 | 55 | 2012 |
| MYCN is an immunosuppressive oncogene dampening the expression of ligands for NK-cell-activating receptors in human high-risk neuroblastoma E Brandetti, I Veneziani, O Melaiu, A Pezzolo, A Castellano, R Boldrini, ... Oncoimmunology 6 (6), e1316439, 2017 | 51 | 2017 |
| DNAM-1 activating receptor and its ligands: how do viruses affect the NK cell-mediated immune surveillance during the various phases of infection? L Cifaldi, M Doria, N Cotugno, S Zicari, C Cancrini, P Palma, P Rossi International journal of molecular sciences 20 (15), 3715, 2019 | 50 | 2019 |
